PMGC Holdings (ELAB) Liabilities and Shareholders Equity (2022 - 2026)
PMGC Holdings (ELAB) posted Liabilities and Shareholders Equity of $26.0 million for Q1 2026, up 102.3% sequentially from $12.9 million in Q4 2025, and up 192.88% YoY from $8.9 million in Q1 2025.
PMGC Holdings (ELAB) Liabilities and Shareholders Equity (2022 - 2026) Analysis & Trends
PMGC Holdings has reported Liabilities and Shareholders Equity for 5 years, with the latest figure at $26.0 million in Q1 2026.
- Quarterly Liabilities and Shareholders Equity rose 192.88% year-over-year to $26.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $63.2 million (up 85.02% YoY) and the FY2025 annual result came in at $12.9 million, up 43.09% from the prior year.
- Liabilities and Shareholders Equity rose to $26.0 million in Q1 2026 per ELAB's latest filing, from $12.9 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $1.6 billion in Q3 2023 and troughed at $1.9 million in Q4 2022.
- A 5-year average of $141.0 million and a median of $9.2 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
- The sharpest annual moves came in 2024 and 2026: Liabilities and Shareholders Equity plunged 99.29% in 2024, then jumped 192.88% in 2026.
- Over 5 years, Liabilities and Shareholders Equity stood at $1.9 million in 2022, then surged by 174.28% to $5.2 million in 2023, then jumped by 73.28% to $9.0 million in 2024, then surged by 43.09% to $12.9 million in 2025, then soared by 102.3% to $26.0 million in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $26.0 million, $12.9 million, and $14.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | PMGC Holdings | 31.22 Mn | 12.43 Mn | 385,691.00 | 36.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.03 Mn |
| Dec 31, 2025 | 12.87 Mn |
| Sep 30, 2025 | 14.94 Mn |
| Jun 30, 2025 | 9.38 Mn |
| Mar 31, 2025 | 8.89 Mn |
| Dec 31, 2024 | 8.99 Mn |
| Sep 30, 2024 | 11.21 Mn |
| Jun 30, 2024 | 5.08 Mn |
| Mar 31, 2024 | 4.23 Mn |
| Dec 31, 2023 | 5.19 Mn |
| Sep 30, 2023 | 1.58 Bn |
| Dec 31, 2022 | 1.89 Mn |